par Coussement, Gauthier;Catherine, Julien
;Roufosse, Florence 
Référence Journal of leukocyte biology, 116, 5, page (1021-1032)
Publication Publié, 2024-11-01


Référence Journal of leukocyte biology, 116, 5, page (1021-1032)
Publication Publié, 2024-11-01
Article révisé par les pairs
Titre: |
|
Auteur: | Coussement, Gauthier; Catherine, Julien; Roufosse, Florence |
Informations sur la publication: | Journal of leukocyte biology, 116, 5, page (1021-1032) |
Statut de publication: | Publié, 2024-11-01 |
Sujet CREF: | Sciences bio-médicales et agricoles |
Mots-clés: | anti-IL-5 |
compassionate use | |
hypereosinophilic syndrome | |
mepolizumab | |
MeSH keywords: | Humans |
Hypereosinophilic Syndrome -- drug therapy | |
Antibodies, Monoclonal, Humanized -- therapeutic use -- adverse effects -- administration & dosage | |
Male | |
Female | |
Middle Aged | |
Adult | |
Aged | |
Retrospective Studies | |
Compassionate Use Trials | |
Treatment Outcome | |
Interleukin-5 -- antagonists & inhibitors | |
Langue: | Anglais |
Identificateurs: | urn:issn:0741-5400 |
info:doi/10.1093/jleuko/qiae152 | |
info:pii/7708691 | |
info:pmid/38970502 |